Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2021

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Summary of Revenue Disaggregated by Segment, Product and Geography

The following table presents the Company's revenue disaggregated by segment, product and geography (in thousands):

Biomedical market:

	Three Months Ended March 31, 2021
					Total		% of Total
	Domestic		International		Revenues		Revenues
Biomedical products
Cells	$	165	$	158	$	323		23	%
Media		973		131		1,104		77	%
Total	$	1,138	$	289	$	1,427		100	%

	Three Months Ended March 31, 2020
					Total		% of Total
	Domestic		International		Revenues		Revenues
Biomedical products
Cells	$	262	$	117	$	379		19	%
Media		1,466		125		1,591		81	%
Total	$	1,728	$	242	$	1,970		100	%

Anti-aging market:

	Three Months Ended March 31,
	2021					2020
	Total		% of Total			Total		% of Total
	Revenues		Revenues			Revenues		Revenues
Skin care sales channels
Ecommerce	$	166		72	%	$	224		57	%
Professional		65		28	%		166		43	%
Total	$	231		100	%	$	390		100	%

Summary of Antidilutive Securities not Included in Diluted Net Loss Per Share Calculation

For the three months ended March 31, 2021 and 2020, the following common stock options, common stock warrants and convertible preferred stock were not included in the diluted net loss per share calculation because the effect would be anti-dilutive.

	Three Months Ended March 31,
	2021		2020
Options outstanding		4,225,757		4,837,580
Common stock warrants outstanding		—		3,951,052
Redeemable convertible preferred stock		2,457,143		2,457,143
Non-redeemable convertible preferred stock		3,675,135		3,675,135
Total		10,358,035		14,920,910